BioCentury | Apr 8, 2021
Finance

With $95M second fund and incubator, Japan-focused Remiges helps start-ups take flight

...a handful of Japanese and U.S. pharmas: Taiho Pharmaceutical Co. Ltd., Sumitomo...
BioCentury | Feb 27, 2021
Emerging Company Profile

Orna: turning circular RNAs into therapies

...than linear RNAs and immune cell therapies. MPM Capital, which seeded and incubated the start-up, and Taiho...
...and Dan AndersonAcademic collaborators: MITCorporate partners: N/ANumber of employees: 25Funds raised: over $100 millionInvestors: MPM Capital, Taiho...
BioCentury | Feb 24, 2021
Product Development

Feb. 23 Quick Takes: Hold for bluebird; plus priority review for Pfizer’s TicoVac and updates from Taiho and NeuroRx

...to the company. The PDUFA date is in August.Taiho’s pimitespib meets in GIST studyPimitespib (TAS-116) from Taiho Pharmaceutical Co. Ltd....
...due to critical COVID-19 if trends seen at 28 days read through to 60 days. BC Staff Taiho Pharmaceutical Co. Ltd. Pfizer...
BioCentury | Feb 13, 2021
Product Development

Howdy partner: MD Anderson’s evolving industry collaboration strategy

...Ingelheim GmbH and Taiho Pharmaceutical Co. Ltd. each have partnerships with MD Anderson that involve the TRACTION platform; Taiho’s...
BioCentury | Jan 16, 2021
Product Development

Jan. 15 Quick Takes: Darzalex gains first FDA approval for form of amyloidosis; plus Thermo Fisher, Lilly, DBV, Dr. Reddy’s, Alexion, Taiho, Astellas-Actinium

...distribution rights in India.Taiho breaks ground in EuropeTaiho Pharmaceutical Co. Ltd. opened a new headquarters, Taiho...
...Peanut (DBV-712) Ultomiris, ravulizumab-cwvz (ALXN1210) Darzalex Faspro, DARA-PH20, subcutaneous daratumumab DBV Technologies S.A. Thermo Fisher Scientific Groupe Novasep S.A.S. Alexion Pharmaceuticals Inc. Taiho Pharmaceutical Co. Ltd....
BioCentury | Jan 8, 2021
Finance

Jan. 8 Quick Takes: Venture rounds for Abbisko, DiCE, Aulos, LifeMine, Mana, Theolytics and more

...pivotal trial for recurrent H3 K27M-mutant glioma. A confirmatory response rate evaluation is expected this year. Epidarex, Taiho...
...Taiho Ventures, with participation from existing investor Oxford Sciences Innovation (OSI).  Epidarex’s Henning Steinhagen and Taiho...
BioCentury | Jan 7, 2021
Finance

Werewolf’s conditionally-activated cancer therapies draw $72M series B, partnering interest

...Sphera Healthcare and CaaS Capital. Returning investors from its $56 million series A are Longwood Fund, Taiho...
BioCentury | Oct 17, 2020
Deals

Oct. 16 Quick Takes: Dren Bio’s $60M series A; plus Roche, Synairgen, Astellas-iota and more

...A round led by SR One and Taiho...
BioCentury | Jun 5, 2020
Finance

Founding investors MPM, F2 back Cullinan’s asset-centric approach with $98.5M series B

...similar efficacy through a better therapeutic window. The EGFR inhibitor, which was spun out from Taiho...
...non-small cell lung cancer (NSCLC) study, which the company hopes to complete by year-end (see “Taiho’s...
...Epidermal growth factor receptor FLT3 (CD135) - FMS-like tyrosine kinase 3 ligand Lauren Martz, Senior Editor Taiho...
BioCentury | May 29, 2020
Finance

Taiho’s new modality search engine

...Taiho Ventures is using a recently upsized fund to find cutting edge modalities that take Taiho...
...a prime example of how Taiho Ventures operates as both the corporate venture arm of Taiho Pharmaceutical Co. Ltd....
...Area biotech (see “Arcus Keeps its Independence” ) In a deal facilitated by Taiho Ventures, Taiho...
Items per page:
1 - 10 of 373
BioCentury | Apr 8, 2021
Finance

With $95M second fund and incubator, Japan-focused Remiges helps start-ups take flight

...a handful of Japanese and U.S. pharmas: Taiho Pharmaceutical Co. Ltd., Sumitomo...
BioCentury | Feb 27, 2021
Emerging Company Profile

Orna: turning circular RNAs into therapies

...than linear RNAs and immune cell therapies. MPM Capital, which seeded and incubated the start-up, and Taiho...
...and Dan AndersonAcademic collaborators: MITCorporate partners: N/ANumber of employees: 25Funds raised: over $100 millionInvestors: MPM Capital, Taiho...
BioCentury | Feb 24, 2021
Product Development

Feb. 23 Quick Takes: Hold for bluebird; plus priority review for Pfizer’s TicoVac and updates from Taiho and NeuroRx

...to the company. The PDUFA date is in August.Taiho’s pimitespib meets in GIST studyPimitespib (TAS-116) from Taiho Pharmaceutical Co. Ltd....
...due to critical COVID-19 if trends seen at 28 days read through to 60 days. BC Staff Taiho Pharmaceutical Co. Ltd. Pfizer...
BioCentury | Feb 13, 2021
Product Development

Howdy partner: MD Anderson’s evolving industry collaboration strategy

...Ingelheim GmbH and Taiho Pharmaceutical Co. Ltd. each have partnerships with MD Anderson that involve the TRACTION platform; Taiho’s...
BioCentury | Jan 16, 2021
Product Development

Jan. 15 Quick Takes: Darzalex gains first FDA approval for form of amyloidosis; plus Thermo Fisher, Lilly, DBV, Dr. Reddy’s, Alexion, Taiho, Astellas-Actinium

...distribution rights in India.Taiho breaks ground in EuropeTaiho Pharmaceutical Co. Ltd. opened a new headquarters, Taiho...
...Peanut (DBV-712) Ultomiris, ravulizumab-cwvz (ALXN1210) Darzalex Faspro, DARA-PH20, subcutaneous daratumumab DBV Technologies S.A. Thermo Fisher Scientific Groupe Novasep S.A.S. Alexion Pharmaceuticals Inc. Taiho Pharmaceutical Co. Ltd....
BioCentury | Jan 8, 2021
Finance

Jan. 8 Quick Takes: Venture rounds for Abbisko, DiCE, Aulos, LifeMine, Mana, Theolytics and more

...pivotal trial for recurrent H3 K27M-mutant glioma. A confirmatory response rate evaluation is expected this year. Epidarex, Taiho...
...Taiho Ventures, with participation from existing investor Oxford Sciences Innovation (OSI).  Epidarex’s Henning Steinhagen and Taiho...
BioCentury | Jan 7, 2021
Finance

Werewolf’s conditionally-activated cancer therapies draw $72M series B, partnering interest

...Sphera Healthcare and CaaS Capital. Returning investors from its $56 million series A are Longwood Fund, Taiho...
BioCentury | Oct 17, 2020
Deals

Oct. 16 Quick Takes: Dren Bio’s $60M series A; plus Roche, Synairgen, Astellas-iota and more

...A round led by SR One and Taiho...
BioCentury | Jun 5, 2020
Finance

Founding investors MPM, F2 back Cullinan’s asset-centric approach with $98.5M series B

...similar efficacy through a better therapeutic window. The EGFR inhibitor, which was spun out from Taiho...
...non-small cell lung cancer (NSCLC) study, which the company hopes to complete by year-end (see “Taiho’s...
...Epidermal growth factor receptor FLT3 (CD135) - FMS-like tyrosine kinase 3 ligand Lauren Martz, Senior Editor Taiho...
BioCentury | May 29, 2020
Finance

Taiho’s new modality search engine

...Taiho Ventures is using a recently upsized fund to find cutting edge modalities that take Taiho...
...a prime example of how Taiho Ventures operates as both the corporate venture arm of Taiho Pharmaceutical Co. Ltd....
...Area biotech (see “Arcus Keeps its Independence” ) In a deal facilitated by Taiho Ventures, Taiho...
Items per page:
1 - 10 of 373